➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Dow
Moodys
McKinsey
Merck
Harvard Business School

Last Updated: October 29, 2020

DrugPatentWatch Database Preview

Claims for Patent: 9,416,112

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 9,416,112
Title:2,4-pyrimidinediamine compounds and their uses
Abstract: The present invention provides 2,4-pyrimidinediamine compounds that inhibit the IgE and/or IgG receptor signaling cascades that lead to the release of chemical mediators, intermediates and methods of synthesizing the compounds and methods of using the compounds in a variety of contexts, including in the treatment and prevention of diseases characterized by, caused by or associated with the release of chemical mediators via degranulation and other processes effected by activation of the IgE and/or IgG receptor signaling cascades.
Inventor(s): Singh; Rajinder (Belmont, CA), Argade; Ankush (Foster City, CA), Payan; Donald (Hillsborough, CA), Molineaux; Susan (San Francisco, CA), Holland; Sacha (San Francisco, CA), Clough; Jeffrey (Redwood City, CA), Keim; Holger (Irvine, CA), Bhamidipati; Somasekhar (Foster City, CA), Sylvain; Catherine (San Mateo, CA), Li; Hui (Santa Clara, CA), Rossi; Alexander (Reedsport, OR)
Assignee: Rigel Pharmaceuticals, Inc. (South San Francisco, CA)
Application Number:14/485,045
Patent Claims: 1. A compound according to the formula: ##STR00048## or a salt thereof, wherein: R.sup.2 is selected from phenyl mono-substituted at the 3- or 5-position with an R.sup.8 group and phenyl di- or tri-substituted with the same or different R.sup.8 groups, provided R.sup.2 is not 3,4,5-trimethoxyphenyl; R.sup.4 is phenyl substituted with one or more of the same or different R.sup.8 groups; R.sup.2 and R.sup.4 are different; R.sup.5 is halogen; R.sup.6 is hydrogen; each R.sup.8 is selected from the group consisting of R.sup.a, R.sup.b, --O--(CH.sub.2).sub.m--R.sup.b C(O)NH--(CH.sub.2).sub.m--R.sup.b, --C(O)NH--(CHR.sup.a).sub.m--R.sup.b, --O--(CH.sub.2).sub.m--C(O)NH--(CH.sub.2).sub.m--R.sup.b, --O--(CHR.sup.a).sub.m--C(O)NH--(CHR.sup.a).sub.m--R.sup.b, --NH--(CH.sub.2).sub.m--R.sup.b, --NH--(CHR.sup.a).sub.m--R.sup.b, -; each R.sup.a is independently selected from the group consisting of (C1-C6) alkyl, (C3-C8) cycloalkyl, cyclohexyl, phenyl, (C6-C16) arylalkyl, benzyl, 3-8 membered cycloheteroalkyl, morpholinyl, 4-11 membered cycloheteroalkylalkyl and 5-10 membered heteroaryl; each R.sup.b is independently selected from the group consisting of --OR.sup.d, (C1-C3) haloalkyloxy, halogen, --CF.sub.3, --S(O)R.sup.d, --S(O).sub.2R.sup.d, --S(O).sub.2OR.sup.d, --S(O).sub.2NR.sup.cR.sup.c, --OS(O)R.sup.d, --OS(O).sub.2R.sup.d, --OS(O).sub.2OR.sup.d, --OS(O).sub.2NR.sup.cR.sup.c, --C(O)R.sup.d, --C(O)OR.sup.d, --C(O)NR.sup.cR.sup.c, --OC(O)R.sup.d, --OC(O)OR.sup.d, --OC(O)NR.sup.cR.sup.c, --OC(NH)NR.sup.cR.sup.c; each R.sup.c is independently hydrogen or R.sup.a; each R.sup.d is independently hydrogen or R.sup.a; and each m is independently an integer from 1 to 3.

2. The compound of claim 1, wherein R.sup.2 is phenyl di-substituted with the same or different R.sup.8 groups.

3. The compound of claim 1, wherein R.sup.2 is 3,4-disubstituted.

4. The compound of claim 1, wherein R.sup.4 is mono-substituted with an R.sup.8 group.

5. The compound of claim 4, wherein R.sup.4 is ortho-substituted with the R.sup.8 group.

6. The compound of claim 4, wherein R.sup.4 is meta-substituted with the R.sup.8 group.

7. The compound of claim 4, wherein R.sup.4 is para-substituted with the R.sup.8 group.

8. The compound of claim 1, wherein R.sup.5 is fluoro.

9. A pharmaceutical composition comprising a compound according to claim 1 and a pharmaceutically acceptable carrier, diluent or excipient.

10. The composition of claim 9, wherein the compound is in the form of a pharmaceutically acceptable salt.

11. The compound of claim 5, wherein R.sup.5 is fluoro.

12. The compound of claim 5, wherein R.sup.5 is chloro.

13. The compound of claim 1, wherein R.sup.2 is phenyl tri-substituted with the same or different R.sup.8 groups.

14. The compound of claim 13, wherein R.sup.4 is mono-substituted with an R.sup.8 group.

15. The compound of claim 14, wherein R.sup.4 is mono-substituted with an R.sup.8 group.

16. The compound of claim 14, wherein R.sup.4 is ortho-substituted with the R.sup.8 group.

17. The compound of claim 14, wherein R.sup.4 is meta-substituted with the R.sup.8 group.

18. The compound of claim 14, wherein R.sup.4 is para-substituted with the R.sup.8 group.

19. The compound of claim 15, wherein R.sup.5 is fluoro.

20. The compound of claim 15, wherein R.sup.5 is chloro.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Baxter
Harvard Business School
Johnson and Johnson
Colorcon
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.